PRX-102在小鼠模型上对小纤维神经病变有阳性效果

发布时间：2018-03-06 01:08

  本文选题：PRX-　切入点：生物制药公司　出处：《国际药学研究杂志》2017年05期 　论文类型：期刊论文

【摘要】：正Protalix生物制药公司新临床前研究证实,PRX-102与市售有效酶替代疗法联用在Fabry小鼠模型上对小纤维神经病变有阳性效果。PRX-102 1 mg/kg与阿加糖苷酶β(β-agalsidese,Fabrazyme)1 mg/kg联用,和阿加糖苷酶α(α.agalsidase,Replagal)0.2 mg/kg比较,对给药Fabry小鼠、不给药Fabry小鼠和对照野生型小鼠的
[Abstract]:A new preclinical study by Protalix Biopharmaceutical Company confirmed that PRX-102 combined with marketable effective enzyme replacement therapy had positive effects on small fibrous neuropathy in Fabry mice model. PRX-1021 mg/kg was used in combination with 尾 -agalsidase 尾 (尾 -agalsideseto Fabrazyme 1 mg/kg), and was compared with agar glycosidase 伪 (伪. Agalsidase Replagalus 0. 2 mg/kg). For Fabry mice, Fabry mice and wild control mice
【分类号】：R965
，

本文编号：1572663